Gleason score and docetaxel response in advanced hormone-sensitive prostate cancer: The lower the better
Received Date : 02 Dec 2018
Accepted Date : 20 Jun 2019
Doi: 10.1016/j.jons.2019.06.001 - Article's Language: EN
J Oncol Sci 5 (2019) 45-48
This is an open access article under the CC BY-NC-ND license
Aim: Recently, three randomized controlled trials evaluated the addition of docetaxel to ADT in advanced hormone-sensitive prostate cancer (aHSPC). Interestingly, all trials showed a trend towards improved OS in the subgroup of patients with Gleason <8 tumors. We herein performed a meta-analysis of these trials to assess the OS benefit of docetaxel in different Gleason score groups (<8 vs ≥8). Material and Method: We searched the Pubmed and Medline databases and ASCO conference proceedings (through February 1st 2018) for relevant trials. For each study, median OS values and hazard ratios (HR) with 95% confidence intervals (CI) collected across different Gleason score groups. We combined the HRs from each of the three eligible trials in the meta-analysis using the random-effect model. Results: Three eligible studies were included in the analyses (CHAARTED, GETUG-AFU-15, and STAMPEDE). In the meta-analysis of three studies, docetaxel-based chemotherapy plus ADT was associated with improved OS [HR: 0.74; 95% CI: 0.62-0.87; p<0.001]. Among patients with tumor Gleason score <8, addition of docetaxel to ADT significantly improved overall survival [HR: 0.66, 95% CI: 0.52–0.85, p=0.001]. Although there was a trend towards improved OS with docetaxel in patients with Gleason score of ≥8, the magnitude of risk reduction was lower and did not achieve statistical significance [HR: 0.81, 95% CI: 0.64–1.02, p=0.066]. Conclusion: In this meta-analysis, OS benefit with the addition of docetaxel to ADT was more prominent in Gleason score <8 tumors. We propose that Gleason score can be a useful criteria for treatment selection in patients with aHSPC.
  1. Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortalityworldwide: sources, methods and major patterns in GLOBOCAN 2012. Int JCancer. 2014;136:E359eE386. [Crossref]  [PubMed]  [PMC] 
  2. Yamamoto T, Musunuru HB, Vesprini D, et al. Metastatic prostate cancer in meninitially treated with active surveillance. J Urol. 2016;195:1409e1414. [Crossref]  [PubMed] 
  3. Siegel RL, Miller KD, Jemal A. Cancer statistics. Ca - Cancer J Clin. 2015;65:5e29,2015. [Crossref]  [PubMed] 
  4. Norum J, Nieder C. Treatments for metastatic prostate cancer (mPC): a review of costing evidence. Pharmacoeconomics. 2017;35:1223e1236. [Crossref]  [PubMed] 
  5. Reese DM. Choice of hormonal therapy for prostate cancer. Lancet. 2000;355: 1474e1475. [Crossref] 
  6. Harris WP, Mostaghel EA, Nelson PS, Montgomery B. Androgen deprivation therapy: progress in understanding mechanisms of resistance and optimizing androgen depletion. Nat Clin Pract Urol. 2009;6:76e85. [Crossref]  [PubMed]  [PMC] 
  7. Isaacs JT, Coffey DS. Adaptation <em>versus</em> selection as the mechanism responsible for the relapse of prostatic cancer to androgen ablation therapy as studied in the dunning R-3327-H adenocarcinoma. Cancer Res. 1981;41:5070.
  8. Tucci M, Bertaglia V, Vignani F, et al. Addition of docetaxel to androgen deprivation therapy for patients with hormone-sensitive metastatic prostate cancer: a systematic review and meta-analysis. Eur Urol. 2016;69:563e573. [Crossref]  [PubMed] 
  9. James ND, Sydes MR, Clarke NW, et al. Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial. The Lancet. 2016;387:1163e1177.
  10. Fizazi K, Tran N, Fein L, et al. Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer. N Engl J Med. 2017;377:352e360. [Crossref]  [PubMed] 
  11. Sydes MR, Spears MR, Mason MD, et al. Adding abiraterone or docetaxel to long-term hormone therapy for prostate cancer: directly randomised data from the STAMPEDE multi-arm, multi-stage platform protocol. Ann Oncol. 2018;29:1235e1248. [Crossref]  [PubMed]  [PMC] 
  12. Sweeney CJ, Chen Y-H, Carducci M, et al. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer. N Engl J Med. 2015;373:737e746. [Crossref]  [PubMed]  [PMC] 
  13. Gravis G, Fizazi K, Joly F, et al. Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial. Lancet Oncol. 2013;14:149e158. [Crossref] 
  14. Fizazi K, Faivre L, Lesaunier F, et al. Androgen deprivation therapy plus docetaxel and estramustine versus androgen deprivation therapy alone for highrisk localised prostate cancer (GETUG 12): a phase 3 randomised controlled trial. Lancet Oncol. 2015;16:787e794. [Crossref] 
  15. Sandler HM, Hu C, Rosenthal SA, et al. A phase III protocol of androgen suppression (AS) and 3DCRT/IMRT versus AS and 3DCRT/IMRT followed by chemotherapy (CT) with docetaxel and prednisone for localized, high-risk prostate cancer (RTOG 0521). J Clin Oncol. 2015;33. LBA5002-LBA. [Crossref] 
  16. Higgins JPT, Sterne JAC, Savovic J, et al. A revised tool for assessing risk of bias in randomized trials. Cochrane Database Syst Rev. 2016;10:29e31.
  17. Tannock IF, de Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 2004;351: 1502e1512. [Crossref]  [PubMed] 
  18. Petrylak DP, Tangen CM, Hussain MHA, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med. 2004;351:1513e1520. [Crossref]  [PubMed] 
  19. Gleason DF, Mellinger GT, Arduino LJ, et al. Prediction of prognosis for prostatic adenocarcinoma by combined histological grading and clinical staging. J Urol. 1974;111:58e64.
  20. Humphrey PA. Gleason grading and prognostic factors in carcinoma of the prostate. Mod Pathol. 2004;17:292. [Crossref]  [PubMed] 
  21. Rusthoven CG, Carlson JA, Waxweiler TV, et al. The prognostic significance of Gleason scores in metastatic prostate cancer. Urol Oncol: Semin. Orig. Invest. 2014;32:707e713. [Crossref]  [PubMed]  [PMC] 
  22. Glass TR, Tangen CM, Crawford ED, Thompson IAN. Metastatic carcinoma of the prostate: identifying prognostic groups using recursive partitioning. J Urol. 2003;169:164e169. [Crossref] 
  23. Halabi S, Small EJ, Kantoff PW, et al. Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer. J Clin Oncol. 2003;21:1232e1237. [Crossref]  [PubMed] 
  24. Rydzewska LHM, Burdett S, Vale CL, et al. Adding Abiraterone to Androgen Deprivation Therapy in Men with Metastatic Hormone-Sensitive Prostate Cancer: A Systematic Review and Meta-Analysisvol. 84. Oxford, England: European journal of cancer; 2017:88e101, 1990.
  25. Feyerabend S, Saad F, Li T, et al. Survival benefit, disease progression and quality-of-life outcomes of abiraterone acetate plus prednisone versus docetaxel in metastatic hormone-sensitive prostate cancer: a network meta-analysis. Eur J Cancer. 2018;103:78e87. [Crossref]  [PubMed]